Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

NCT01661868 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Drug not available.

Conditions

Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions

DRUG: Olaparib

Sponsor

Dana-Farber Cancer Institute